The verdict
Our read at a glance.
Whether blocking myostatin and its related ligands with a decoy receptor can build or preserve muscle at a dose that does not also cause vascular side effects.
- The signal
- ACE-031 is a fusion protein of activin receptor type IIB and IgG1-Fc that binds myostatin and related ligands. In a randomized, double-blind, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy, investigators observed trends toward maintenance of six-minute walk distance against decline on placebo, along with increases in lean body mass and bone mineral density and reduced fat mass. That is real pharmacodynamic activity in humans, which distinguishes this memo from most of the muscle category.
- The unknown
- Whether a dose exists that separates the muscle effect from the vascular one. The trial stopped before that question could be answered, so the therapeutic window was never established and no later program resolved it.
- Our read
- The honest counterexample in this category. It is the strongest human signal for myostatin inhibition building muscle, and it is also the clearest demonstration that hitting this pathway broadly has consequences outside muscle. Both halves belong in the same sentence.
The mechanism
How it works.
Safety & regulatory boundary
The consequential part.
The trial was halted after the second dosing regimen over potential safety concerns of epistaxis and telangiectasias. Notably these were not classed as serious or severe adverse events, and the program stopped anyway, which is the part worth understanding: the sponsor judged non-muscle vascular effects unacceptable in this population. ACE-031 is not approved anywhere and is not in active development. Material sold under this name is not the studied biologic and its identity cannot be assumed.
What's next
What we're watching.
Nothing is pending for ACE-031 itself. The live question is whether newer, more selective myostatin and activin programs avoid the vascular effects; bimagrumab and trevogrumab on this Watchlist are where that plays out.
Context
Why this is discussed.
It is the compound bodybuilding forums point to when arguing that myostatin inhibition works, and the trial data behind that argument is genuinely more substantial than for most compounds in this space.
The evidence base
3 cited references.
Regulatory & labels1
U.S. Food and Drug Administration · Current FDA page
Indexed literature (PubMed)2
Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. (Muscle Nerve) · 2017
Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, et al. (BMC Musculoskelet Disord) · 2017
Keep reading